Pulmonary Pharmacology & Therapeutics

Papers
(The H4-Index of Pulmonary Pharmacology & Therapeutics is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy – CONTROL study73
Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)40
Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers37
CG223, a novel BET inhibitor, exerts TGF-β1-mediated antifibrotic effects in a murine model of bleomycin-induced pulmonary fibrosis36
Shedding light on vitamin D in tuberculosis: A comprehensive review of clinical trials and discrepancies30
Evaluation of body weight–based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin d26
Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients25
Pharmacokinetic variability of CFTR modulators from standard and alternative regimens23
The inflammatory regulation of TRPA1 expression in human A549 lung epithelial cells21
S1PR1 attenuates pulmonary fibrosis by inhibiting EndMT and improving endothelial barrier function20
Editorial Board19
Editorial Board19
Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential18
Chronic obstructive pulmonary disease and emerging ER stress-related therapeutic targets18
Editorial Board18
The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study17
Comparing the outcomes of intrapleural fibrinolytic and DNase therapy versus intrapleural fibrinolytic or DNase therapy: A systematic review and meta-analysis17
0.057538032531738